4 research outputs found
The metabolic syndrome is not associated with homocysteinemia: The Persian Gulf Healthy Heart Study
Background: It is uncertain whether homocysteine
and the metabolic syndrome or its components are related
in the general population, as studies investigating the
association between homocysteine levels and insulin resistance
have shown conflicting results. Methods: In an ancillary
study to the Persian Gulf Healthy Heart Study, a cohort
study of Iranian men and women aged ≥25 yr, a random sample
of 1754 subjects were evaluated for the association of
plasma homocysteine levels and the metabolic syndrome using
National Cholesterol Education Program (NCEP)-Adult
Treatment Panel (ATP)-III criteria. Total homocysteine levels
and high sensitivity C-reactive protein (CRP) were determined
by enzyme-linked immunosorbent assays. Results: Subjects
with lower HDL-cholesterol and higher blood pressure
showed significantly higher homocysteine levels (p=0.001
and p<0.0001; respectively). There was no significant difference
in serum levels of homocysteine between subjects with
and without the metabolic syndrome. In multiple logistic regression
analysis, the metabolic syndrome did not show a
significant association with serum homocysteine levels after
adjusting for sex, age, smoking, fruit and vegetable intake
pattern, body mass index, and physical inactivity. Concurrent
elevated CRP levels and the metabolic syndrome also did not
show a significant association with serum homocysteine levels
after adjusting for sex, age, and lifestyle cardiovascular
risk factors. Conclusions: There was no association between
the metabolic syndrome using NCEP-ATPIII criteria and homocysteinemia
in this study. These data refute the hypothesis
that homocysteine levels are influenced by the metabolic
syndrome, at least in general healthy population
Effect of tamoxifen on fibrinogen, D-dimer, lipid and lipoprotein concentrations in breast cancer patients
The metabolic syndrome is not associated with homocysteinemia: The Persian Gulf Healthy Heart Study
Genomic Analysis of Non-NF2 Meningiomas Reveals Mutations in TRAF7, KLF4, AKT1, and SMO
We report genomic analysis of 300 meningiomas, the most common primary brain tumors, leading to the discovery of mutations in TRAF7, a proapoptotic E3 ubiquitin ligase, in nearly one-fourth of all meningiomas. Mutations in TRAF7commonly occurred with a recurrent mutation (K409Q) in KLF4, a transcription factor known for its role in inducing pluripotency, or with AKT1(E17K), a mutation known to activate the PI3K pathway. SMO mutations, which activate Hedgehog signaling, were identified in ~5% of non-NF2 mutant meningiomas. These non-NF2 meningiomas were clinically distinctive—nearly always benign, with chromosomal stability, and originating from the medial skull base. In contrast, meningiomas with mutant NF2 and/or chromosome 22 loss were more likely to be atypical, showing genomic instability, and localizing to the cerebral and cerebellar hemispheres. Collectively, these findings identify distinct meningioma subtypes, suggesting avenues for targeted therapeutics